TABLE 1.

Demographic and clinical characteristics according to AD phenotype

	EOAD	PCA	lvPPA	LOAD
N	53	52	29	42
Age	61.5±4.4	62.6±7.6	67.0±7.7^a	75.8±3.0^b
Sex (% male)	55.2	58.5	59.5	51.9
Education^*	5.3±1.0	5.0±1.1	4.7±1.5	4.9±1.3
MMSE	21.5±5.4	22.2±3.4	21.8±4.3	22.1±3.9
CDR	0.7±0.3	0.8±0.2	0.9±0.2	0.8±0.2
TIV (L)	1.56±0.13	1.57±0.14	1.61±0.14	1.57±0.14
CSF Aβ₄₂(ng/L)^**	480±90	459±98	469±117	433±103
CSF Total tau (ng/L)	695±358	728±309	788±376	785±336
% CSF total tau >375	84.9	92.3	85.7	90.5
CSF Phospho tau (ng/L)	92±40	93±38	96±34	97±39
% CSF phospho tau >52	79.2	90.4	93.1	90.5

Abbreviations: PCA = Posterior cortical atrophy; lvPPA = Logopenic variant primary progressive aphasia; EOAD = Early-onset Alzheimer’s disease; LOAD = Late-onset Alzheimer’s disease; MMSE = Mini-mental state examination; CDR = Clinical dementia rating scale; TIV = Total intracranial volume.

Data are presented as mean ± SD unless otherwise stated. Differences between groups were analyzed using ANOVA with post-hoc Bonferroni tests (age, MMSE, CDR, TIV, CSF), X² tests (sex), Kruskal-Wallis with post-hoc Mann-Whitney U-tests (education) and bootstrapping (% of suprathreshold CSF concentrations).

using Verhage’s classification (scale 1–7(Verhage, 1964)),

^**

Only patients with CSF Aβ₄₂ <640 were included,

lvPPA > PCA & EOAD, p<0.01;

LOAD > all other groups, p<0.001.